{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:44:39Z","timestamp":1781779479109,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fibroblast growth factor receptor 3 is known as a favorable aim in vast range of cancers, particularly in bladder cancer treatment. Pharmacophore and QSAR modeling approaches are broadly utilized for developing novel compounds for the determination of inhibitory activity versus the biological target. In this study, these methods employed to identify FGFR3 potential inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To find the potential compounds for bladder cancer targeting, ZINC and NCI databases were screened. Pharmacophore and QSAR modeling of FGFR3 inhibitors were utilized for dataset screening. Then, with regard to several factors such as Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties and Lipinski\u2019s Rule of Five, the recognized compounds were filtered. In further step, utilizing the flexible docking technique, the obtained compounds interactions with FGFR3 were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The best five compounds, namely ZINC09045651, ZINC08433190, ZINC00702764, ZINC00710252 and ZINC00668789 were selected for Molecular Dynamics (MD) studies. Off-targeting of screened compounds was also investigated through CDD search and molecular docking. MD outcomes confirmed docking investigations and revealed that five selected compounds could make steady interactions with the FGFR3 and might have effective inhibitory potencies on FGFR3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These compounds can be considered as candidates for bladder cancer therapy with improved therapeutic properties and less adverse effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-03955-5","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T15:04:34Z","timestamp":1676041474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Mahmoud","family":"Ganji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohreh","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Shoari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-4184","authenticated-orcid":false,"given":"Reza","family":"Ahangari Cohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"3","key":"3955_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3955_CR2","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034370.","journal-title":"SAGE Open Med"},{"issue":"6","key":"3955_CR3","volume":"4","author":"G Zheng","year":"2021","unstructured":"Zheng G, Sundquist K, Sundquist J, F\u00f6rsti A, Hemminki O, Hemminki K. Bladder and upper urinary tract cancers as first and second primary cancers. Cancer Rep. 2021;4(6): e1406.","journal-title":"Cancer Rep"},{"issue":"4","key":"3955_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420\u201333.","journal-title":"Eur Urol"},{"issue":"4","key":"3955_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4103\/0970-1591.166445","volume":"31","author":"S Isharwal","year":"2015","unstructured":"Isharwal S, Konety B. Non-muscle invasive bladder cancer risk stratification. Indian J Urol. 2015;31(4):289.","journal-title":"Indian J Urol"},{"issue":"3","key":"3955_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.currproblcancer.2014.06.001","volume":"38","author":"JC Park","year":"2014","unstructured":"Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle invasive bladder cancer. Curr Probl Cancer. 2014;38(3):80.","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"3955_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104.","journal-title":"Eur Urol"},{"issue":"1","key":"3955_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","volume":"13","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel). 2021;13(1):131.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3955_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4111\/icu.2018.59.5.285","volume":"59","author":"HS Kim","year":"2018","unstructured":"Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol. 2018;59(5):285\u201396.","journal-title":"Investig Clin Urol"},{"issue":"1","key":"3955_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):1\u201335.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"3955_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215\u201366.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"issue":"25","key":"3955_CR12","doi-asserted-by":"publisher","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","volume":"271","author":"DM Ornitz","year":"1996","unstructured":"Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996;271(25):15292\u20137.","journal-title":"J Biol Chem"},{"issue":"1","key":"3955_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF\/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5(1):1\u201338.","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"3955_CR14","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.3390\/cancers13225796","volume":"13","author":"J Szymczyk","year":"2021","unstructured":"Szymczyk J, Sluzalska KD, Materla I, Opalinski L, Otlewski J, Zakrzewska M. FGF\/FGFR-dependent molecular mechanisms underlying anti-cancer drug resistance. Cancers (Basel). 2021;13(22):5796.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3955_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/path.5143","volume":"246","author":"M Foth","year":"2018","unstructured":"Foth M, Ismail NFB, Kung JSC, Tomlinson D, Knowles MA, Eriksson P, et al. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation. J Pathol. 2018;246(3):331\u201343.","journal-title":"J Pathol"},{"issue":"11","key":"3955_CR16","doi-asserted-by":"publisher","first-page":"e1711","DOI":"10.1634\/theoncologist.2020-0334","volume":"25","author":"R Garje","year":"2020","unstructured":"Garje R, An J, Obeidat M, Kumar K, Yasin HA, Zakharia Y. Fibroblast growth factor receptor (FGFR) inhibitors in urothelial cancer. Oncologist. 2020;25(11):e1711\u20139.","journal-title":"Oncologist"},{"issue":"1","key":"3955_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"B Wang","year":"2021","unstructured":"Wang B, Wu H, Hu C, Wang H, Liu J, Wang W, et al. An overview of kinase downregulators and recent advances in discovery approaches. Signal Transduct Target Ther. 2021;6(1):1\u201319.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"3955_CR18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","volume":"26","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, Hollebecque A, Bahleda R, Loriot Y, Olaussen KA, Massard C, et al. Facts and new hopes on selective FGFR inhibitors in solid tumorsselective FGFR inhibitors in solid tumors. Clin Cancer Res. 2020;26(4):764\u201374.","journal-title":"Clin Cancer Res"},{"key":"3955_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/JRLCR.S46845","volume":"7","author":"A Gaurav","year":"2014","unstructured":"Gaurav A, Gautam V, Pereira S, Alvarez-Leite J, Vetri F, Choudhury M, et al. Structure-based three-dimensional pharmacophores as an alternative to traditional methodologies. J Recept Ligand Channel Res. 2014;7:27\u201338.","journal-title":"J Recept Ligand Channel Res"},{"key":"3955_CR20","volume-title":"Quantitative structure-activity relationship (QSAR): modeling approaches to biological applications","author":"SC Peter","year":"2019","unstructured":"Peter SC, Dhanjal JK, Malik V, Radhakrishnan N, Jayakanthan M, Sundar D. Quantitative structure-activity relationship (QSAR): modeling approaches to biological applications. Amsterdam: Elsevier; 2019."},{"key":"3955_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-022-03252-y","author":"P De","year":"2022","unstructured":"De P, Kar S, Ambure P, Roy K. Prediction reliability of QSAR models: an overview of various validation tools. Arch Toxicol. 2022. https:\/\/doi.org\/10.1007\/s00204-022-03252-y.","journal-title":"Arch Toxicol"},{"issue":"6","key":"3955_CR22","doi-asserted-by":"publisher","first-page":"13407","DOI":"10.3390\/ijms160613407","volume":"16","author":"N Zhou","year":"2015","unstructured":"Zhou N, Xu Y, Liu X, Wang Y, Peng J, Luo X, et al. Combinatorial pharmacophore-based 3D-QSAR analysis and virtual screening of FGFR1 inhibitors. Int J Mol Sci. 2015;16(6):13407\u201326.","journal-title":"Int J Mol Sci"},{"key":"3955_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116019","volume":"33","author":"I Kuriwaki","year":"2021","unstructured":"Kuriwaki I, Kameda M, Iikubo K, Hisamichi H, Kawamoto Y, Kikuchi S, et al. Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency. Bioorg Med Chem. 2021;33: 116019.","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"3955_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41589-019-0455-7","volume":"16","author":"L Chen","year":"2020","unstructured":"Chen L, Marsiglia WM, Chen H, Katigbak J, Erdjument-Bromage H, Kemble DJ, et al. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. Nat Chem Biol. 2020;16(3):267\u201377.","journal-title":"Nat Chem Biol"},{"key":"3955_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2021.1899049","author":"L Huang","year":"2021","unstructured":"Huang L, Wu X, Fu X, Wang H, Tang B, Xiao Y, et al. Ligand based 3D-QSAR model, pharmacophore, molecular docking and ADME to identify potential fibroblast growth factor receptor 1 inhibitors. J Biomol Struct Dyn. 2021. https:\/\/doi.org\/10.1080\/07391102.2021.1899049.","journal-title":"J Biomol Struct Dyn"},{"key":"3955_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.860985","author":"J Zheng","year":"2022","unstructured":"Zheng J, Zhang W, Li L, He Y, Wei Y, Dang Y, et al. Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review. Front Chem. 2022. https:\/\/doi.org\/10.3389\/fchem.2022.860985.","journal-title":"Front Chem"},{"issue":"1","key":"3955_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-017-0654-2","volume":"18","author":"S Sato","year":"2017","unstructured":"Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H, et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res. 2017;18(1):1\u201311.","journal-title":"Respir Res"},{"key":"3955_CR28","volume-title":"4: LigPrep","author":"S Release","year":"2019","unstructured":"Release S. 4: LigPrep. New York: Schr\u00f6dinger; 2019."},{"issue":"8","key":"3955_CR29","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1021\/ct300203w","volume":"8","author":"D Shivakumar","year":"2012","unstructured":"Shivakumar D, Harder E, Damm W, Friesner RA, Sherman W. Improving the prediction of absolute solvation free energies using the next generation OPLS force field. J Chem Theory Comput. 2012;8(8):2553\u20138.","journal-title":"J Chem Theory Comput"},{"issue":"10","key":"3955_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10822-006-9087-6","volume":"20","author":"SL Dixon","year":"2006","unstructured":"Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des. 2006;20(10):647\u201371.","journal-title":"J Comput Aided Mol Des"},{"key":"3955_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2020.128271","volume":"1216","author":"S Beura","year":"2020","unstructured":"Beura S, Chetti P. Identification of potential human COX-2 inhibitors using computational modeling and molecular dynamics simulations. J Mol Struct. 2020;1216: 128271.","journal-title":"J Mol Struct"},{"issue":"10","key":"3955_CR32","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1080\/07391102.2020.1772111","volume":"39","author":"S Beura","year":"2021","unstructured":"Beura S, Chetti P. In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2. J Biomol Struct Dyn. 2021;39(10):3747\u201359.","journal-title":"J Biomol Struct Dyn"},{"issue":"7","key":"3955_CR33","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/jcc.21707","volume":"32","author":"CW Yap","year":"2011","unstructured":"Yap CW. PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem. 2011;32(7):1466\u201374.","journal-title":"J Comput Chem"},{"key":"3955_CR34","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1590\/S0103-50532012005000073","volume":"23","author":"CA Nunes","year":"2012","unstructured":"Nunes CA, Freitas MP, Pinheiro ACM, Bastos SC. Chemoface: a novel free user-friendly interface for chemometrics. J Braz Chem Soc. 2012;23:2003\u201310.","journal-title":"J Braz Chem Soc"},{"issue":"6","key":"3955_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/cem.3226","volume":"34","author":"T Mehmood","year":"2020","unstructured":"Mehmood T, S\u00e6b\u00f8 S, Liland KH. Comparison of variable selection methods in partial least squares regression. J Chemom. 2020;34(6): e3226.","journal-title":"J Chemom"},{"issue":"7","key":"3955_CR36","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"LG Ferreira","year":"2015","unstructured":"Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384\u2013421.","journal-title":"Molecules"},{"key":"3955_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume-title":"Chemical biology","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. In: Hempel JE, Williams CH, Hong CC, editors. Chemical biology. New York: Springer; 2015. p. 243\u201350."},{"issue":"13","key":"3955_CR38","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605\u201312.","journal-title":"J Comput Chem"},{"issue":"3","key":"3955_CR39","first-page":"258","volume":"69","author":"\u0141P Fus","year":"2016","unstructured":"Fus \u0141P, G\u00f3rnicka B. Role of angiogenesis in urothelial bladder carcinoma. Cent Eur J Urol. 2016;69(3):258.","journal-title":"Cent Eur J Urol"},{"key":"3955_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1:19\u201325.","journal-title":"SoftwareX"},{"issue":"12","key":"3955_CR41","doi-asserted-by":"publisher","DOI":"10.1063\/1.4978807","volume":"146","author":"Y Lin","year":"2017","unstructured":"Lin Y, Pan D, Li J, Zhang L, Shao X. Application of Berendsen barostat in dissipative particle dynamics for nonequilibrium dynamic simulation. J Chem Phys. 2017;146(12): 124108.","journal-title":"J Chem Phys"},{"issue":"12","key":"3955_CR42","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. LINCS: a linear constraint solver for molecular simulations. J Comput Chem. 1997;18(12):1463\u201372.","journal-title":"J Comput Chem"},{"issue":"12","key":"3955_CR43","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden T, York D, Pedersen L. Particle mesh Ewald: an N\u22c5 log (N) method for Ewald sums in large systems. J Chem Phys. 1993;98(12):10089\u201392.","journal-title":"J Chem Phys"},{"key":"3955_CR44","unstructured":"Turner PJ. XMGRACE, version 5.1. 19. Cent Coast Land-Margin Res Oregon Grad Inst Sci Technol Beaverton, OR. 2005;2."},{"issue":"9","key":"3955_CR45","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/bioinformatics\/bty816","volume":"35","author":"A Vangone","year":"2019","unstructured":"Vangone A, Schaarschmidt J, Koukos P, Geng C, Citro N, Trellet ME, et al. Large-scale prediction of binding affinity in protein\u2013small ligand complexes: the PRODIGY-LIG web server. Bioinformatics. 2019;35(9):1585\u20137.","journal-title":"Bioinformatics"},{"issue":"1","key":"3955_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10822-017-0049-y","volume":"32","author":"Z Kurkcuoglu","year":"2018","unstructured":"Kurkcuoglu Z, Koukos PI, Citro N, Trellet ME, Rodrigues J, Moreira IS, et al. Performance of HADDOCK and a simple contact-based protein\u2013ligand binding affinity predictor in the D3R Grand Challenge 2. J Comput Aided Mol Des. 2018;32(1):175\u201385.","journal-title":"J Comput Aided Mol Des"},{"issue":"1","key":"3955_CR47","first-page":"82","volume":"40","author":"WL Lano","year":"2002","unstructured":"Lano WL. Pymol: an open-source molecular graphics tool. CCP4 Newsl Protein Crystallogr. 2002;40(1):82\u201392.","journal-title":"CCP4 Newsl Protein Crystallogr."},{"issue":"11","key":"3955_CR48","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.str.2013.08.026","volume":"21","author":"EV Bocharov","year":"2013","unstructured":"Bocharov EV, Lesovoy DM, Goncharuk SA, Goncharuk MV, Hristova K, Arseniev AS. Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies. Structure. 2013;21(11):2087\u201393.","journal-title":"Structure"},{"key":"3955_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmolb.2015.00020","volume":"2","author":"P Craveur","year":"2015","unstructured":"Craveur P, Joseph AP, Esque J, Narwani TJ, No\u00ebl F, Shinada N, et al. Protein flexibility in the light of structural alphabets. Front Mol Biosci. 2015;2:20.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"3955_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/12615","volume":"23","author":"D Cappellen","year":"1999","unstructured":"Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23(1):18\u201320.","journal-title":"Nat Genet"},{"issue":"2","key":"3955_CR51","doi-asserted-by":"publisher","first-page":"W407","DOI":"10.1093\/nar\/gkm290","volume":"35","author":"M Wiederstein","year":"2007","unstructured":"Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(2):W407\u201310.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"3955_CR52","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"G Xiong","year":"2021","unstructured":"Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49(W1):W5-14.","journal-title":"Nucleic Acids Res"},{"issue":"39","key":"3955_CR53","doi-asserted-by":"publisher","first-page":"20387","DOI":"10.1074\/jbc.M116.743138","volume":"291","author":"SM Lamothe","year":"2016","unstructured":"Lamothe SM, Guo J, Li W, Yang T, Zhang S. The human ether-a-go-go-related gene (hERG) potassium channel represents an unusual target for protease-mediated damage. J Biol Chem. 2016;291(39):20387\u2013401.","journal-title":"J Biol Chem"},{"key":"3955_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/484963","volume":"2015","author":"FG Hoosain","year":"2015","unstructured":"Hoosain FG, Choonara YE, Tomar LK, Kumar P, Tyagi C, du Toit LC, et al. Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. Biomed Res Int. 2015;2015:1.","journal-title":"Biomed Res Int"},{"issue":"5","key":"3955_CR55","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1021\/acs.jmedchem.8b01263","volume":"62","author":"DA Smith","year":"2018","unstructured":"Smith DA, Beaumont K, Maurer TS, Di L. Clearance in drug design: miniperspective. J Med Chem. 2018;62(5):2245\u201355.","journal-title":"J Med Chem"},{"issue":"6","key":"3955_CR56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1053\/beog.2001.0231","volume":"15","author":"M Dawes","year":"2001","unstructured":"Dawes M, Chowienczyk PJ. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15(6):819\u201326.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"3955_CR57","volume-title":"StatPearls","author":"G Price","year":"2021","unstructured":"Price G, Patel DA. Drug bioavailability. In: Price G, editor. StatPearls. Treasure Island: StatPearls Publishing; 2021."},{"issue":"15","key":"3955_CR58","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1021\/acs.jmedchem.5b00201","volume":"58","author":"DA Smith","year":"2015","unstructured":"Smith DA, Beaumont K, Maurer TS, Di L. Volume of distribution in drug design: miniperspective. J Med Chem. 2015;58(15):5691\u20138.","journal-title":"J Med Chem"},{"key":"3955_CR59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/B978-0-323-98367-9.00012-3","volume-title":"Pharmacokinetics and toxicokinetic considerations","author":"K Rajpoot","year":"2022","unstructured":"Rajpoot K, Desai N, Koppisetti H, Tekade M, Sharma MC, Behera SK, et al. In silico methods for the prediction of drug toxicity. In: Tekade RK, editor., et al., Pharmacokinetics and toxicokinetic considerations. Amsterdam: Elsevier; 2022. p. 357\u201383."},{"issue":"W1","key":"3955_CR60","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257\u201363.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"3955_CR61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF00332351","volume":"47","author":"G Zbinden","year":"1981","unstructured":"Zbinden G, Flury-Roversi M. Significance of the LD50-test for the toxicological evaluation of chemical substances. Arch Toxicol. 1981;47(2):77\u201399.","journal-title":"Arch Toxicol"},{"key":"3955_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-0716-1960-5_4","volume-title":"Silico methods for predicting drug toxicity","author":"S Kar","year":"2022","unstructured":"Kar S, Roy K, Leszczynski J. In silico tools and software to predict ADMET of new drug candidates. In: Benfenati E, editor. Silico methods for predicting drug toxicity. New York: Springer; 2022. p. 85\u2013115."},{"issue":"4","key":"3955_CR63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1134\/S0026893308040195","volume":"42","author":"MY Lobanov","year":"2008","unstructured":"Lobanov MY, Bogatyreva NS, Galzitskaya OV. Radius of gyration as an indicator of protein structure compactness. Mol Biol. 2008;42(4):623\u20138.","journal-title":"Mol Biol"},{"issue":"3","key":"3955_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1501240","volume":"2","author":"D Chen","year":"2016","unstructured":"Chen D, Oezguen N, Urvil P, Ferguson C, Dann SM, Savidge TC. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci Adv. 2016;2(3): e1501240.","journal-title":"Sci Adv"},{"key":"3955_CR65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-62703-658-0_11","volume-title":"Protein dynamics","author":"CC David","year":"2014","unstructured":"David CC, Jacobs DJ. Principal component analysis: a method for determining the essential dynamics of proteins. In: Livesay DR, editor. Protein dynamics. Totowa: Humana Press; 2014. p. 193\u2013226."},{"issue":"12","key":"3955_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00894-018-3858-6","volume":"24","author":"V Zarezade","year":"2018","unstructured":"Zarezade V, Abolghasemi M, Rahim F, Veisi A, Behbahani M. In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment. J Mol Model. 2018;24(12):1\u201319.","journal-title":"J Mol Model"},{"issue":"5","key":"3955_CR67","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0609.2011.01586.x","volume":"86","author":"E De Braekeleer","year":"2011","unstructured":"De Braekeleer E, Douet-Guilbert N, Rowe D, Bown N, Morel F, Berthou C, et al. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol. 2011;86(5):361\u201371.","journal-title":"Eur J Haematol"},{"key":"3955_CR68","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20198324","author":"JX Chen","year":"2019","unstructured":"Chen JX, Yi XJ, Gu PL, Gao SX. The role of KDR in intrauterine adhesions may involve the TGF-\u03b21\/Smads signaling pathway. Braz J Med Biol Res. 2019. https:\/\/doi.org\/10.1590\/1414-431x20198324.","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"3955_CR69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/molehr\/gal010","volume":"12","author":"KJ Hutt","year":"2006","unstructured":"Hutt KJ, McLaughlin EA, Holland MK. Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod. 2006;12(2):61\u20139.","journal-title":"Mol Hum Reprod"},{"issue":"9","key":"3955_CR70","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc1169","volume":"3","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650\u201365.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3955_CR71","doi-asserted-by":"publisher","first-page":"175","DOI":"10.31662\/jmaj.2020-0021","volume":"3","author":"M Takahashi","year":"2020","unstructured":"Takahashi M, Kawai K, Asai N. Roles of the RET proto-oncogene in cancer and development. JMA J. 2020;3(3):175\u201381.","journal-title":"JMA J"},{"issue":"4","key":"3955_CR72","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1210\/jc.2012-4085","volume":"98","author":"MB Lodish","year":"2013","unstructured":"Lodish MB. Kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab. 2013;98(4):1333\u201342.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3955_CR73","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/cancers12030731","volume":"12","author":"C Pottier","year":"2020","unstructured":"Pottier C, Fresnais M, Gilon M, J\u00e9rusalem G, Longuesp\u00e9e R, Sounni NE. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers (Basel). 2020;12(3):731.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3955_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7150\/ijms.1.101","volume":"1","author":"MK Paul","year":"2004","unstructured":"Paul MK, Mukhopadhyay AK. Tyrosine kinase\u2013role and significance in cancer. Int J Med Sci. 2004;1(2):101.","journal-title":"Int J Med Sci"},{"issue":"15","key":"3955_CR75","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3390\/cancers13153737","volume":"13","author":"P Linn","year":"2021","unstructured":"Linn P, Kohno S, Sheng J, Kulathunga N, Yu H, Zhang Z, et al. Targeting RB1 loss in cancers. Cancers (Basel). 2021;13(15):3737.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3955_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):1\u201320.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"3955_CR77","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846685","volume":"20","author":"J Jung","year":"2019","unstructured":"Jung J, Cho K, Naji AK, Clemons KN, Wong CO, Villanueva M, et al. HRAS-driven cancer cells are vulnerable to TRPML1 inhibition. EMBO Rep. 2019;20(4): e46685.","journal-title":"EMBO Rep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03955-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-03955-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03955-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T11:14:59Z","timestamp":1676286899000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-03955-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3955"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-03955-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"29 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}